| Mrs Kathleen Frances Vaught, OTR/L | |
|
2040 Us Route 50, Batavia, OH 45103-8694 | |
| (513) 239-0990 | |
| Not Available |
| Full Name | Mrs Kathleen Frances Vaught |
|---|---|
| Gender | Female |
| Speciality | Occupational Therapist |
| Location | 2040 Us Route 50, Batavia, Ohio |
| Accepts Medicare Assignments | Does not participate in Medicare Program. She may not accept medicare assignment. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1962068585 | NPI | - | NPPES |
| OT005690 | Medicaid | OH |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 225X00000X | Occupational Therapist | OT005690 (Ohio) | Primary |
| Mailing Address | Practice Location Address |
|---|---|
| Mrs Kathleen Frances Vaught, OTR/L 2040 Us Route 50, Batavia, OH 45103-8694 Ph: (513) 239-0990 | Mrs Kathleen Frances Vaught, OTR/L 2040 Us Route 50, Batavia, OH 45103-8694 Ph: (513) 239-0990 |
News Archive
Human white blood cells, engineered to recognize other malignant immune cells, could provide a novel therapy for patients with highly lethal B cell cancers such as acute lymphoblastic leukemia (ALL), according to researchers at Memorial Sloan-Kettering Cancer Center (MSKCC).
Exploiting artificial intelligence (AI) to develop tools for improving the monitoring of treatment of rare, progressive, and highly debilitating diseases such as Friedreich's (FRDA) and spinocerebellar ataxia (SCA).
Researchers at Johns Hopkins and George Washington universities report new evidence that proteins created by defective forms of HIV long previously believed to be harmless actually interact with our immune systems and are actively monitored by a specific type of immune cell, called cytotoxic T cells.
The University of Texas MD Anderson Cancer Center today announced that it has entered into a collaborative research and development agreement with Enumeral Biomedical Holdings Inc.
AVEO Pharmaceuticals, Inc., a biopharmaceutical company focused on discovering, developing and commercializing cancer therapeutics, today announced that it has achieved its enrollment target for TIVO-1, its global Phase 3 clinical trial for its oral, triple VEGF receptor inhibitor, tivozanib, in patients with advanced renal cell carcinoma. In February of this year, AVEO initiated enrollment in TIVO-1, and has successfully reached the target enrollment of 500 patients.
› Verified 3 days ago
Mrs. Carrie E. Scroggins, M.S., OTR/L Occupational Therapist Medicare: Not Enrolled in Medicare Practice Location: 2400 Clermont Center Dr, Batavia, OH 45103 Phone: 513-735-8300 | |
Ms. Martha Leigh Owens, OTR/L Occupational Therapist Medicare: Not Enrolled in Medicare Practice Location: 4202 Christopher Ct, Batavia, OH 45103 Phone: 513-732-6612 | |
Angela Sager, Occupational Therapist Medicare: Not Enrolled in Medicare Practice Location: 2400 Clermont Center Dr, Batavia, OH 45103 Phone: 513-735-8330 | |
Mrs. Rebecca Brock, OTR/L Occupational Therapist Medicare: Not Enrolled in Medicare Practice Location: 2400 Clermont Center Dr, Batavia, OH 45103 Phone: 513-735-8300 | |
Lindsay Lemon, Occupational Therapist Medicare: Not Enrolled in Medicare Practice Location: 2400 Clermont Center Dr, Batavia, OH 45103 Phone: 740-441-7400 | |
Rebecca Beyer, Occupational Therapist Medicare: Not Enrolled in Medicare Practice Location: 2400 Clermont Center Dr Ste 100, Batavia, OH 45103 Phone: 513-735-8300 | |
Tara Murdock, MOT, OTR/L Occupational Therapist Medicare: Not Enrolled in Medicare Practice Location: 2400 Clermont Center Dr, Batavia, OH 45103 Phone: 513-735-8300 |